Why is Sellas Life Sciences stock surging today?
Sellas Life Sciences (SLS) stock surged 245.1% in pre-market trading after its Phase 3 REGAL trial of galinpepimut-S met its primary endpoint, showing a 41% reduction in death risk. The company plans to engage with the FDA for an accelerated filing strategy. The stock was halted before resuming higher.
How this was made
The 30-second read
Why it matters
Meeting the primary overall survival endpoint with statistical significance, coupled with a stated FDA engagement and accelerated filing plan, is a direct catalyst for valuation and trading positioning. The reported tolerability and lack of new safety signals reduce a key overhang.
Market read
Traders have a same-session, company-specific clinical and regulatory catalyst explaining a large pre-market surge and potential continuation risk.
What to watch
The article does not quantify magnitude of benefit versus specific best-available treatment details, nor does it address potential subgroup effects, durability, or how FDA may condition accelerated approval.
Background
REGAL is Sellas Life Sciences’ Phase 3 trial of galinpepimut-S (GPS), an immunotherapeutic cancer vaccine targeting AML.
Ticker impact
Sellas Life Sciences shares surged pre-open after its Phase 3 REGAL trial met the primary overall survival endpoint for galinpepimut-S (GPS).
Likely continued upside pressure early as traders price in accelerated filing prospects, with elevated volatility risk after the initial halt/resumption.
The article reports a statistically significant Phase 3 overall survival improvement (hazard ratio 0.59, p=0.035), removal of safety overhang, and a concrete plan to engage FDA and prepare a BLA in 1H 2027.
Market effects
Reinforces positive read-through for AML immunotherapy vaccine approaches and can lift sentiment toward clinical-stage biotech with late-stage data catalysts.
Limited direct macro linkage; broader indices described as modestly mixed/neutral.
Primarily US biotech regulatory and clinical-trial sentiment, with limited spillover beyond comparable oncology vaccine developers.
Counterpoint
A single Phase 3 endpoint and accelerated filing intent may not fully de-risk FDA review; investors could fade the move if confirmatory evidence or manufacturing/CMC questions emerge.
Key entities
- companySellas Life Sciences
Subject of the article; GPS Phase 3 REGAL met primary overall survival endpoint and outlined FDA accelerated filing plans.
- productGalinpepimut-S (GPS)
Immunotherapeutic cancer vaccine targeting AML evaluated in the Phase 3 REGAL trial.
- regulatorU.S. Food and Drug Administration (FDA)
Company plans to engage with FDA to pursue an accelerated filing strategy and prepare a BLA in 1H 2027.

